Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 9/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | METTL3 | Q86U44 | 2/20 | 0.58 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
| ▸ | TTR | P02766 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | FABP2 | P12104 | 1/20 | 0.58 |
| ▸ | RXRA | P19793 | 1/20 | 0.58 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.58 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | PDE4A | P27815 | 1/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.58 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.58 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.58 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9735867 | 0.83 | PTGS2 (0.53) | PTGS2MEN1MAPK1KMT2AMETTL3 | |
| SCHEMBL24021583 | 0.80 | PTGS2 (0.57) | PTGS2MEN1MAPK1KMT2AMETTL3 | |
| SCHEMBL8611927 | 0.80 | PTGS2 (0.44) | PTGS2MEN1MAPK1KMT2AMETTL3 | |
| SCHEMBL2760397 | 0.79 | PTGS2 (0.65) | PTGS2MEN1MAPK1KMT2AMETTL3 | |
| SCHEMBL24021602 | 0.78 | MEN1 (0.56) | PTGS2MEN1MAPK1KMT2AMETTL3 | |
| SCHEMBL14618510 | 0.78 | PTGS2 (0.53) | PTGS2MEN1MAPK1KMT2APTGS1 | |
| SCHEMBL8611985 | 0.77 | PTGS2 (0.42) | PTGS2MEN1MAPK1KMT2AMETTL3 | |
| SCHEMBL22140749 | 0.77 | CLCN2 (0.62) | PTGS2MEN1MAPK1KMT2AMETTL3 | |
| SCHEMBL20694079 | 0.75 | PTGS2 (0.60) | PTGS2MEN1MAPK1KMT2AMETTL3 | |
| SCHEMBL2419050 | 0.74 | HSD17B10 (0.52) | PTGS2MEN1MAPK1KMT2AAKR1B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2409149-B1 | METHODS OF SCREENING USING AMPHIBIANS | BRÄNDLI ANDRÉ W (CH) | 2015-11-11 | — | — | EP | disclosed |
| US-6552077-B2 | Kidney disorders | EXOCELL, INC. | 2003-04-22 | — | — | US | disclosed |
| EP-1242069-A2 | ALBUMIN-BINDING COMPOUNDS THAT PREVENT NONENZYMATIC GLYCATION AND THAT MAY BE USED FOR TREATMENT OF GLYCATION-RELATED PATHOLOGIES | EXOCELL, INC. (US) | 2002-09-25 | — | — | EP | disclosed |
| US-6355680-B1 | BLOCKING REACTION OF GLUCOSE AND ALBUMIN | EXOCELL, INC. | 2002-03-12 | — | — | US | disclosed |
| US-20010034359-A1 | Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies | EXOCELL, INC. | 2001-10-25 | — | — | US | disclosed |
| WO-2001003684-A2 | ALBUMIN-BINDING COMPOUNDS THAT PREVENT NONENZYMATIC GLYCATION AND THAT MAY BE USED FOR TREATMENT OF GLYCATION-RELATED PATHOLOGIES | EXOCELL, INC. (US) | 2001-01-18 | — | — | WO | disclosed |
| US-5462952-A | Have activity as inhibitors of 5-lipoxygenase and/or cyclooxygenase | WARNER-LAMBERT COMPANY (US) | 1995-10-31 | — | — | US | disclosed |
| US-5155110-A | Antiinflammatory agents, analgesics, antipyretics | WARNER-LAMBERT COMPANY (US) | 1992-10-13 | — | — | US | disclosed |
| EP-0316630-A1 | Novel fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition | WARNER-LAMBERT COMPANY (US) | 1989-05-24 | — | — | EP | disclosed |
| WO-1989003818-A1 | NOVEL FENAMIC ACID HYDROXAMATE DERIVATIVES HAVING CYCLOOXYGENASE AND 5-LIPOXYGENASE INHIBITION | WARNER-LAMBERT COMPANY (US) | 1989-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034359-A1 | Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies | ALB, AGER, TTR | PTGS2 2067/4885MEN1 3564/4885MAPK1 2536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.